Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma.
David J ChungNina ShahJuan WuBrent R LoganLina BisharatNatalie S CallanderGiulia CheloniKenneth C AndersonThinle ChodonBinod DhakalSteven M DevinePoorvi Somaiya DuttYvonne A EfeberaNancy L GellerHaider GhiasuddinPeiman HemattiLeona HolmbergAlan HowardBryon JohnsonDimitra KaragkouniHillard M LazarusEhsan MalekPhilip L McCarthyDavid H McKennaAdam MendizabalAjay K NookaNikhil C MunshiLynn O'DonnellAaron P RapoportJane ReeseJacalyn RosenblattRobert J SoifferDina StroopinskyLynne UhlIoannis S VlachosEdmund K WallerJames W YoungMarcelo C PasquiniDavid AviganPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
DC/MM fusion vaccination with lenalidomide did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating MM-reactive lymphocytes indicative of tumor-specific immunity. Site-specific production of a personalized cell therapy with centralized product characterization was effectively accomplished in the context of a multicenter cooperative group study.